Clouds Over CB Antagonists Cast Light On Rest Of Obesity Pipeline

With big pharma's bet on cannabinoid-1 receptor antagonists for obesity shadowed by the safety concerns behind the withdrawal of Sanofi-Aventis' Zimulti (rimonabant) NDA, the weight of late-stage development could fall on centrally acting drugs that act on extensively-studied neurotransmitters, primarily serotonin, and peripherally acting agents that promise an improved side effect profile